PORTLAND, Maine, March 27, 2019 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle, today announced the pricing of its previously announced underwritten public offering of 1,636,364 shares of common stock of the Company at a price to the public of $5.50 per share. ImmuCell expects to receive aggregate gross proceeds of approximately $9.0 million from the offering. All of the shares of common stock are being offered by ImmuCell. The offering is expected to close on or about March 29, 2019, subject to customary closing conditions.

Craig-Hallum Capital Group is acting as sole managing underwriter for the offering.

The Company intends to use a portion of the net proceeds of the offering for expansion of production capacity for its First Defense^® product line, and it is increasingly likely that it will use a portion of those proceeds for expanded facilities to manufacture Re-Tain™. Any remaining available net proceeds will be used for reduction of indebtedness or general working capital.

About ImmuCell

ImmuCell Corporation's (Nasdaq: ICCC) purpose is to create scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle. ImmuCell markets products that provide Immediate Immunity™ to newborn dairy and beef livestock and is in the late stages of developing a novel treatment for mastitis, the most significant cause of economic loss to the dairy industry. Press releases and other information about the Company are available at: http://www.immucell.com.